[A17-37] Dolutegravir (HIV infection) - Addendum to commission A17-11

Last updated 21.09.2017

Project no.:
A17-37

Commission:
Commission awarded on 10.08.2017 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Immune system and infections

Indication:

HIV infection in children with antiretroviral pretreatment or in treatment-naive children

Result of dossier assessment:

Added benefit still not proven: data from studies in adults not transferable to children

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2017-09-21 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.